Skip to main content
. 2007 Feb 2;189(8):3006–3016. doi: 10.1128/JB.01544-06

FIG. 4.

FIG. 4.

Heterologous expression of bviRG4 and cepRG4 in non-DHL-producing clinical strains using TLC-AHL bioassays with the A. tumefaciens(pCF218)(pCF372) reporter strain. (A) AHL production profile of non-DHL-producing strains complemented with bviRG4 in trans. Lane 1, FC466(pRM284); lane 2, FC466(pUCP28T); lane 3, FC411(pRM284); lane 4, FC441(pUCP28T); lane 5, C2822(pRM284); lane 6, C2822(pUCP28T); lane 7, synthetic standards. (B) AHL production profile of non-DHL-producing strains with cepRG4 in trans. Lane 1, FC466(pRM282); lane 2, FC466(pUCP28T); lane 3, FC411(pRM282); lane 4, FC441(pUCP28T); lane 5, C2822(pRM282); lane 6, C2822(pUCP28T); lane 7, synthetic standards.